GADD45G and esophageal cancer: Research indicates that the expression of GADD45G is frequently reduced in anaplastic thyroid carcinoma (14), gastric cancer, colorectal cancer, pancreatic cancer (15), non-Hodgkin lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, cervical cancer, esophageal cancer, and lung cancer (16).